Predictive factors of breast cancer evaluated by immunohistochemistry

Jornal Brasileiro de Patologia e Medicina Laboratorial

Volumn 44, Issue 2, 2008, Pages 131-140

  Gobbi, Helenice ^a   Rocha, Rafael Malagoli ^b   Nunes, Cristiana Buzelin ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UFMG

Author keywords

Estrogen receptor; Her2 neu; Progesterone receptor

Indexed keywords

EID: 47649108876     PISSN: 16762444     EISSN: 16784774     Source Type: Journal    
DOI: 10.1590/S1676-24442008000200010     Document Type: Review

References (56)

1. ALLRED, D. C. et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol, v. 11, n. 2, p. 155-68, 1998.
2. BANKFALVI, A. et al. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology, v. 37, n. 5, p. 411-19, 2000.
3. BARNES, D. M. et al. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer, v. 74, n. 9, p. 1329-30, 1996.
4. BHARGAVA, R.; LAL, P.; CHEN, B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization? Am J Clin Pathol, v. 123, n. 2, p. 237-43, 2005.
5. BOENISCHT, T. Formalin-fixed and heat-retrieved tissue antigens: a comparison of their immunoreactivity in experimental antibody diluents. Appl Immunohistochem Mol Morphol, v. 9, p. 176-9, 2001.
6. CANO, G. et al. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Diagn Cytopathol, v. 29, n. 4, p. 207-11, 2003.
7. CARLSON, R. W. et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw, v. 4, Suppl 3, S1-22, quiz S23-24, 2006.
8. CHEANG, M.C.U. et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol, v. 24, n. 36, p. 5637-44, 2006.
9. COBLEIGH, M. A. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, v. 17, n. 9, p. 2639-48, 1999.
10. DAKO. DAKO HercepTest: a manual for interpretation. Carpinteria: DAKO, Manual Guideline, 1999.
11. DAKO. DAKO ACIS™ automated cellular imaging system. Available at: http://www.dakogmbh.de, 2007.
12. DANDACHI, N.; DIETZE, O.; HAUSER-KRONBERGER, C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection ofeferences HER2 oncogene in archival human breast carcinoma. Lab Invest, v. 82, n. 8, p. 1007-14, 2002.
13. ELLIS, I. O. et al. Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol, v. 57, n. 3, p. 233-7, 2004.
14. ENMARK, E.; GUSTAFSSON, J-A. Estrogen receptor β: a novel receptor opens up new possibilities for cancer diagnosis and treatment. Endocr Rel Cancer, v. 5, p. 213-22, 1998.
15. FITZGIBBONS, P. L. et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med, v. 124, n. 7, p. 966-78, 2000.
16. GOBBI, H. et al. A comparative study between rabbit monoclonal antibodies and mouse monoclonal antibodies anti-estrogen receptor in breast cancer. Lab Invest, v. 86, p. 28A, 2006.
17. GOBBI H. et al. Breast cancer risk associated with estrogen receptor expression in epithelial hyperplasia lacking atypia and adjacent lobular units. I J Cancer, v. 113, n. 1, p. 857-9, 2005.
18. GOLDHIRSCH, A. et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. J Clin Oncol, v. 19, n. 18, p. 3817-27, 2001.
19. GONG, Y.; GILCREASE, M.; SNEIGE, N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol, v. 18, n. 8, p. 1015-21, 2005.
20. GOUVEA, A. P. et al. HER-2/neu immunoreactivity in invasive mammary carcinomas: a comparative study using monoclonal and polyclonal antibodies including the HercepTest™. J Bras Patol Med Lab, v. 40, n. 1, p. 27-32, 2004.
21. GOUVEA, A. P. et al. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol, v. 14, n. 1, p. 103-8, 2006.
22. HANNA, W. M.; KWOK, K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol, v. 19, n. 4, p. 481-7, 2006.
23. HARVEY, J. N. et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol, v. 17, p. 1474-81, 1999
24. HUANG, Z. et al. Development of new rabbit monoclonal antibody to estrogen receptor. Appl Immunohistochem Mol Morphol, v. 13, p. 91-5, 2005.
25. HUANG, Z. et al. Development of new rabbit monoclonal antibody to progesterone receptor (clone SP2): no heat pretreatment but effect for paraffin section immunohistochemistry. Appl Immunohistochem Mol Morphol, v. 14, n. 2, p. 229-33, 2006.
26. HUANG, Z.; ZHU, W.; MENG, Y. Novel rabbit monoclonal antibody to estrogen receptor (clone SP1): no heat pretreatment but effective on paraffin embedded tissue. Appl Immunohistoch Mol Morphol, v. 13, p. 91-5, 2005.
27. JIMENEZ, R. E. et al. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol, v. 13, n. 1, p. 37-45, 2000.
28. KOUNELIS, S. et al. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry. Anticancer Res, v. 25, n. 2A, p. 939-46, 2005.
29. LAMBROS, M. B. K. et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest, v. 86, n. 4, p. 398-408, 2006.
30. LAMBROS, M. B. K. et al. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Path, v. 38, p. 1105-22, 2007.
31. LEHR, H-A. et al. Application of Photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Hist Cytochem, v. 45, n. 1, p. 1559-65, 1997.
32. LEONG, A.S-Y. Refinement of immunohistologic parameters for Her2/neu scoring validation by FISH and CISH. Appl Immunohistochem Mol Morphol, v. 14, n. 4, p. 384-9, 2006.
33. LOMBARDO, J. F. American Society of Clinical Oncology/College of American Pathologists guidelines should be scientifically validated. Arch Pathol Lab Med, v. 131, n. 10, p. 1510, 2007.
34. LORING, P. et al. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. Appl Immunohistochem Mol Morphol, v. 13, n. 2, p. 194-200, 2005.
35. McCORMICK, S. R. et al. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol, v. 117, n. 6, p. 935-43, 2002.
36. MILLER, R. T.; KUBIER, P. Blocking of endogenous avidin-binding activity in immunohistochemistry: the use of egg whites. Appl Immunohistochem, v. 5, p. 63-6, 1997.
37. MOSKALUK, C. A. Standardization of clinical immunohistochemistry: why, how and by whom? Am J Clin Pathol, v. 118, n. 5, p. 669-71, 2002.
38. NUNES, C. B. et al. Concordância interobservador na interpretação imunohistoquímica da superexpressão do Her2 detectada por cinco diferentes anticorpos em arrays de carcinomas mamários. J Bras Patol Med Lab, v. 43, n. 5, p. 365-71, 2007.
39. PETROSYAN, K.; TAMAYO, R.; JOSEPH, D. Sensitivity of a novel biotin-free detection reagent (powervision+) for immunohistochemistry. J Histotechnol, v. 25, p. 247-50, 2002.
40. PRESS, M. F. et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol, v. 20, n. 14, p. 3095-105, 2002.
41. RHODES, A. et al. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumours: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol, v. 118, p. 408-17, 2002.
42. RHODES, A. et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: inter-laboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol, v. 53, p. 125, 2000.
43. RICARDO, S. et al. HER2 Evaluation through the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol, v. 60, p. 1001-5, 2006.
44. ROCHA, R. M. et al. Construção de arrays de tecido com equipamento alternativo e de baixo custo para estudo imunoistoquímico de tumores mamários. J Bras Patol Med Lab, v. 42, p. 477-82, 2006.
45. ROCHA, R. M. et al. Rabbit monoclonal antibodies are highly cost effective and a reliable alternative to mouse antibodies for estrogen and progesterone receptor evaluation of breast cancer by immunohistochemistry. Lab Invest, v. 87, p. 48A, 2007.
46. ROSSI, S. et al. Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol, v. 124, n. 2, p. 295-302, 2005.
47. SHI, S-R.; COTE, R. J.; TAYLOR, C. R. Antigen retrieval immunohistochemistry: past, present and future. J Histochem Cytochem, v. 45, p. 327-43, 1997.
48. TAFURI, L. S. A. et al. Cell cycle related proteins in hyperplasia of usual type in breast specimens of patients with and without breast cancer. BMC Cell Biol, v. 7, p. 29, 2006.
49. TANNER, M. et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol, v. 157, n. 5, p. 1467-72, 2000.
50. THOMSON, T. A. et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol, v. 14, n. 11, p. 1079-86, 2001.
51. UMEMURA, S. et al. Immunohistochemical evaluation of hormone receptor for routine practice of breast cancer: highly sensitive procedures significantly contribute to the correlation with biochemical assays. Appl Immunohistochem Mol Morphol, v. 11, p. 62-72, 2003.
52. VINCENT-SALOMON, A. et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: Results of the French multicentre GEFPICS study. Histopathology, v. 42, n. 4, p. 337-47, 2003.
53. WANG, S. et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol, v. 53, n. 5, p. 374-81, 2000.
54. WOLFF, A. C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, v. 25, p. 118-45, 2007.
55. ZHAO, J. et al. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol, v.15, n.6, p.657-65, 2002.
56. ZYMED® : Spot-Light® CISH™ Probes and CISH™ Detection. In. South San Francisco; 2005.